Product Name: Lapizole® 20 mg/ml suspension for oral administration

Issue Date: 08/2017



SECTION 1: IDENTIFICATION			
1.1 Product identifier			
Product name:	Lapizole® 20 mg/ml suspension for oral administration		
Synonyms:	Not Available		
Proper Shipping name:	Not Available		
Other means of identification:	None		
1.2 Relevant identified uses	of the substances or mixture and uses advised against		
Recommended uses:	Broad spectrum de-wormer/antiparasiticide. For oral administration in the prevention and treatment of infections caused by internal parasites, including Encephalitozoon cuniculi.		
Uses advised against:	Not for human use. Do not use in animals intended for human consumption. Do not eat the eggs of treated birds.		
	Lapizole is only for use in rabbits, birds, reptiles and ferrets. Do not use in animals other than those indicated. Do not use in pregnant animals. Do not overdose.		
	In birds, fenbendazole can cause intestinal problems and inhibit bone marrow production. Do not use in nestlings/ growing birds or those in moult. In some mammalian species, high doses of fenbendazole can lead to bone marrow suppression, gastrointestinal tract irritation and problems in pregnancy.		
	As with all veterinary medicines, occasional instances of allergic response due to prior sensitisation, drug intolerance and idiosyncratic reactions may occur.		
1.3 Details of the supplier o	f the substance or mixture		
Registered company name:	Dechra Ltd		
Address:	Snaygill Industrial Estate Keighley Road Skipton North Yorkshire BD23 2RW UK		
Telephone:	+44 (0) 1756 791311		

Product Name: Lapizole® 20 mg/ml suspension for oral administration

Issue Date: 08/2017



Fax:	+44 (0) 1756 798604	
Email:	Not available	
1.4 Emergency Telephone Numbers		
	+44 (0) 1756 791311	

	111 (6) 1766 761611		
SECTION 2: HAZARDS IDENTIFICATION			
2.1 Classification of the sub	ostance or mixture		
DSD Classification (EU):	Not Available		
DPD Classification (EU) ¹ :	Not Available		
Classification according to regulation (EC) No 1272/2008 [CLP] (EU) ¹ :	Not Available		
2.2 Label Elements			
Signal Word:	Not Available		
Hazard Statement(s)			
Not Available			
Additional Statement(s)			
Not Available			
Precautionary Statement(s)	Prevention:		
Not Available			
Precautionary Statement(s)	Response:		
Not Available			
Precautionary Statement(s) Storage:			
Not Available			
Precautionary Statement(s)	Disposal:		
Not Available			
2.3 Other Hazard Information Not Available	on		

Product Name: Lapizole® 20 mg/ml suspension for oral administration

Issue Date: 08/2017



SECTION 3: INFORMATION ON THE INGREDIENTS			
3.1 Substances			
See section below for	composition of n	nixtures	
3.2 Mixtures			
1.CAS No 2.EC Number 3.Index Number 4.REACH Number	% weight	Name	Classification according to regulations (EC) No 1272/2008 [CLP] (EU)
1. 43210-67-9 2. 256-145-7 3. Not Available 4. Not Available	2	Fenbendazole	Carcinogenicity Category 2; H351 ¹
Not Applicable	Proprietary	Other ingredients are non-hazardous	N/a

Legend:	1. Classified by Chemwatch		
SECTION 4: FIRST AID MEASURES			
4.1 Description of firs	st aid measures		
Eye contac	In case of accidental contact of the product with the eyes rinse abundantly with fresh water. Seek medical attention if irritation persists, showing the package leaflet or the label to the medical practitioner.		
Skin contac	In case of accidental contact of the product with the skin rinse abundantly with fresh water. Seek medical attention if irritation persists, showing the package leaflet or the label to the medical practitioner.		
Inhalatio	n: Not considered to be a hazard. If inhaled, remove to fresh air and encourage to rest.		
Ingestio	n: Following accidental ingestion, seek medical advice, showing the package leaflet to the medical practitioner.		
4.2 Most important symptoms and effects, both acute and delayed			
See Section 11			
4.3 Indication of immediate medical attention and special treatment needed N/a			

Product Name: Lapizole® 20 mg/ml suspension for oral administration

Issue Date: 08/2017

Version No: 1 Page 1 of 14



SECTION 5: FIRE FIGHTING MEASURES			
5.1 Extinguishing media	5.1 Extinguishing media		
Suitable:	All systems may be used.		
Unsuitable:	None.		
5.2 Special hazards arising from the substance or mixture			
Fire incompatibility:	None known.		
5.3 Special protective actions for fire-fighters:			
Firefighting:	Alert Fire Brigade and tell them location and nature of hazard. Wear full breathing apparatus and self-contained breathing apparatus.		
Fire / explosion hazard:	None.		

SECTION 6: ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures

For information on protective equipment, see section 8.

6.2 Environmental Precautions

Do not allow product to reach sewage system or any water course.

Inform respective authorities in case of seepage into water course or sewage system.

Do not allow to enter sewers/surface or ground water.

6.3 Methods and material for containment and cleaning up

6.3 Methods and material for containment and cleaning up			
Minor Spills:	Clean affected area with water.		
Major Spills: Clean up all spills immediately. Clean affected area with water. For large spills, take precautions to prevent entry into waterway sewers, or surface drainage systems. Control personal contact with the substance, by using protective equipment. Avoid contact with skin and eyes.			

Product Name: Lapizole® 20 mg/ml suspension for oral administration

Issue Date: 08/2017



SECTION 7: HANDLING AND STORAGE			
7.1 Precautions for safe ha	andling		
Safe Handling:	Wear suitable protection gloves and clothing when handling the product. Wash hands after use. When handling, DO NOT eat, drink or smoke. Observe manufacturer's storage and handling recommendations.		
Other Information:	Keep out of the reach and sight of children. Store in a cool, dry, well-ventilated place.		
7.2 Conditions for safe sto	orage, including any incompatibilities		
Suitable Container:	Do not store above 25°C. Do not freeze. Protect from direct sunlight. No in-use shelf life studies have been undertaken on this product.		
Storage incompatibility:	No major incompatibilities known.		
7.3 Specific end uses			
Not available			

SECTION 8: EXPOSURE CONTROLS / PERSONAL PROTECTION		
8.1 Control parameters		
DERIVED NO EFFECT LEVEL - DNEL		
Not Available		
PREDICTED NO EFFECT LEVEL - PNEC		
Not Available		
OCCUPATIONAL EXPOSURE LIMITS (OEL)		

INGREDIENT DATA:	
Not Available	

EMERGENCY LIMITS:				
Ingredient	Material Name	TEEL-1	TEEL-2	TEEL-3
Not Available				

Product Name: Lapizole® 20 mg/ml suspension for oral administration

Issue Date: 08/2017



Ingredient	Original IDLH	Revised IDLH	
Not Available			
8.2 Exposure controls			
	The basic types of engineering controls are: Process controls which involve changing the way a job activity or process is done to reduce the particular risk.		
Personal protection:			
Eye and face protection:	Safety glasses with side shields / chemical goggles		
Skin protection:	See hand protection below		
Hands/ feet protection:	No special equipment needed when handling small quantities. OTHERWISE: Wear chemical protective gloves		
Body protection:	Wear appropriate clothing		
Other protection:	No special equipment needed when handling small quantities		
Thermal hazards:	Not applicable		
Respiratory protection:	Not applicable		
8.3 Environmental exposure controls See Section 12			

Product Name: Lapizole® 20 mg/ml suspension for oral administration

Issue Date: 08/2017

Version No: 1 Page 1 of 14



SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on basic physical and chemical properties

Appearance: Lapizole®: Light green liquid

Fenbendazole: a white, or almost white, powder

Container: Polypropylene container containing 100 ml of suspension and a dosing syringe.

Physical state: Lapizole®: Liquid

Odour: Not available

Odour Threshold: Not available pH (as supplied): Not available

Melting point / freezing point (degrees C): Not available Initial boiling point and boiling range: Not available

Flash Point: Not available Evaporation rate: Not available Flammability: Not available

Upper/lower flammability or explosive limits: Not available

Vapour pressure: Not available

Relative Density (at degrees C): Not available

Solubility in water and solvents (mg/l): Fenbendazole: practically insoluble

Vapour density: Not available

Auto ignition temperature (degrees C): Not available Decomposition temperature (degrees C): Not available

Viscosity: (degrees C): Not available Explosive properties: Not available Oxidising properties: Not available Partition Coefficient: Not available

Molecular weight: Fenbendazole: 299.37

Taste: Not available

Surface tension: Not available **Volative component:** Not available

Gas group: Not available pH as a solution: Not available

VOC g/L: Not available

9.2 Other information

Not Available

10: REACTIVITY AND STABILITY		
10.1 Reactivity:	See Section 7	
10.2 Chemical stability:	Product is considered stable.	
10.3 Possibility of hazardous reactions:	Stable under normal temperatures and conditions.	
10.4 Conditions to avoid:	Protect from direct sunlight.	
10.5 Incompatible materials:	See section 7.	

Product Name: Lapizole® 20 mg/ml suspension for oral administration

See Section 5.

Issue Date: 08/2017

Version No: 1 Page 1 of 14

10.6 Hazardous



decomposition:	See Section 5.			
SECTION 11: TOXICOLOGICAL INFORMATION				
Inhalation:	Not consid	dered to be a hazard.		
		ardous if swallowed in lar	ge amounts.	
Skin contact:		rial is not thought to proc	luce adverse health effects or skin	
Eye contact:	Directives characteri), direct contact with the	nt to be an irritant (as classified by EC eye may cause transient discomfort ctival redness (as with windburn). Slight	
Chronic:	Encephalitozoon cuniculi is a protozoal parasite of rabbits which affects the nervous and urinary systems and can cause a number of clinical signs. These include, but are not limited to, head tilt, hind limb paralysis or weakness, eye problems and death. It is a common parasite which is frequently sub-clinical, but in one study over 50% of rabbits in the UK were shown to have been infected. Encepalitozoon cuniculi may be passed on to humans and presents a potential risk to individuals who may have deficiencies to the immune system.			
Lignol [®] :	Acute to	cicity	Irritation	
	Not Availa	able	Not Available	
Lidocaine hydrochloride:	Acute toxicity Irritation			
	Oral (rat)	LD ₅₀ : >10000 mg/kg ¹	Not Available	
1.* Value obtained from manufacturer's SDS. Unless otherwise specified, data extracted from RTECS - Register of Toxic Effect of chemical Substances				
Skin corrosion/ in	ritation:			
Not available				
Serious eye damage/ irritation:				
Not available				
Respiratory or skin sensitization:				
Not available				
Germ cell mutagenicity:				
Not available				
Carcinogenicity:				
No data available				

Product Name: Lapizole® 20 mg/ml suspension for oral administration

Issue Date: 08/2017

Version No: 1 Page 1 of 14



SECTION 11: TOXICOLOGICAL INFORMATION		
Reproductive toxicity:		
Not available		
STOT – single exposure:		
Not available		
STOT-repeated exposure:		
Not available		
Aspiration hazard:		
Not available		

SECTION 12: ECOLOGICAL INFORMATION	
12.1 Toxicity	
Not Available	
12.2 Persistence and degradability	
Not Available	
12.3 Bioaccumulative potential	

12.3 Bioaccumulative potentia	
-------------------------------	--

Not Available

12.4 Mobility in Soil

Not Available

12.5 Results of PBT and vPvB assessment

Not Available

12.6 Other adverse effects

Not Available

SECTION 13: DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods

Product / Any unused veterinary medicinal product or waste material derived from packaging such veterinary medicinal products should be disposed of in accordance disposal: with national requirements.

Legislation addressing waste disposal requirements may differ by

Product Name: Lapizole® 20 mg/ml suspension for oral administration

Issue Date: 08/2017



	country, state and/ or territory. Each user must refer to laws operating in their area.
	Ensure that the disposal of material is carried out in accordance with Hazardous Substances (Disposal) Regulations 2001.
Waste Treatment Options:	
Sewage Disposal Options:	

SECTION 14: TRANSPORT INFORMATION		
Labels required:	None	
Marine pollutant:	NO	
Hazchem:	Not Applicable	

Land transport (ADR):			
14.1 UN Number	N/a		
14.2 UN Proper Shipping Name	N/a		
14.3 Transport	Class	N/a	
hazard class(es)	Sub risk	N/a	
14.4 Packing group	N/a		
14.5 Environmental hazards	N/a		
14.6 Special precautions for	Special provisions	N/a	
user	Classification code	N/a	
	Hazard Label	N/a	
	Special provisions	N/a	
	Limited quantity	N/a	

Product Name: Lapizole® 20 mg/ml suspension for oral administration

Issue Date: 08/2017 Version No: 1 Page 1 of 14



14.7 Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code	N/a		
Air transport (ICAO-I	ATA / DGR):		
14.1 UN Number	N/a		
14.2 UN Proper Shipping Name	N/a		
14.3 Transport	ICAO/IATA Class	N/a	
hazard class(es)	ICAO / IATA Sub risk	N/a	
	ERG Code	N/a	
14.4 Packing group	N/a		
14.5 Environmental hazards	N/a		
	Special provisions	N/a	
precautions for user	Cargo only packing instructions	N/a	
	Cargo only maximum qty/pack	N/a	
	Passenger and cargo packaging instructions	N/a	
	Passenger and cargo maximum qty/pack	N/a	
	Passenger and cargo limited quantity packing instructions	N/a	
	Passenger and cargo limited maximum qty/pack	N/a	
14.7 Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code	N/a		
Sea transport (IMDG	-Code / GGVSee):		
14.1 UN Number	N/a		
14.2 UN Proper Shipping Name	N/a		

Product Name: Lapizole® 20 mg/ml suspension for oral administration

Issue Date: 08/2017



14.3 Transport	IMDG Class	N/a		
hazard class(es)	IMDG Sub risk			
14.4 Packing group		1 7 0		
14.5 Environmental hazards				
14.6 Special	EMS Number	N/a		
precautions for user	Special provisions	N/a		
	Limited quantities	N/a		
14.7 Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code	N/a			
Inland waterways tra	nsport (ADN):			
14.1 UN Number	N/a			
14.2 UN Proper Shipping Name	N/a			
14.3 Transport hazard class(es)	N/a N/a			
14.4 Packing group	N/a			
14.5 Environmental hazard		N/a		
14.6 Special	Classification Code N/a		N/a	
precautions for user	Special provisions		N/a	
	Limited quantity N/a Equipment required N/a		N/a	
			N/a	
	Fire cones number N/a		N/a	
14.7 Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code				

Product Name: Lapizole® 20 mg/ml suspension for oral administration

Issue Date: 08/2017

Version No: 1 Page 1 of 14



SECTION 15: REGULATORY INFORMATION

15.1 Safety, health and environmental regulations / legislation specific for the substance or mixture

FENBENDAZOLE (43210-67-9) IS FOUND ON THE FOLLOWING REGULATORY LISTS:

- European Customs Inventory of Chemical Substances ECICS (English)
- European Union European Inventory of Existing Commercial Chemical Substances (EINECS) (English)

15.2 Chemical Safety Assessment

ECHA SUMMARY

Ingredient	CAS number	Index Number	ECHA Dossier
Fenbendazole	73-78-9	Not Available	Not Available

Harmonization (C&L Inventory)	Hazard Class and Category Code(s)	Pictograms Signal Word Code(s)	Hazard Statement Code(s)
1	Repr. 2, Aquatic Acute 1, Aquatic Chronic 1	GHS09, GHS08, Wng	H361, H410
2	Repr. 2, Aquatic Acute 1, Aquatic Chronic 1, Aquatic Chronic 3, STOT RE 2, Carc. 2, Not Classified	GHS09, GHS08, Dgr	H361, H410, H373, H400, H351, H341

Harmonization Code 1 = The most prevalent classification. Harmonization Code 2 = The most severe classification

Australia - AICS	Υ
Canada - DSL	Υ
Canada - NDSL	N (fenbendazole)
China - IECSC	N (fenbendazole)
Europe - EINEC / ELINCS / NLP	Y
Japan - ENCS	N (fenbendazole)
Korea - KECI	Υ
New Zealand - NZIoC	Υ
Philippines - PICCS	N (fenbendazole)

Product Name: Lapizole® 20 mg/ml suspension for oral administration

Issue Date: 08/2017

Version No: 1 Page 1 of 14



USA - TSCA	N (fenbendazole)
	Y = All ingredients are on the inventory N = Not determined or one or more ingredients are not on the inventory and are not exempt from listing(see specific ingredients in brackets)

SECTION 16: OTHER INFORMATION

The SDS is written in accordance to guidelines specified by REACH, GHS and ECHA.

For detailed advice on Personal Protective Equipment, refer to the following EU CEN Standards:

EN 166 Personal eye-protection

EN 340 Protective clothing

EN 374 Protective gloves against chemicals and micro-organisms

EN 13832 Footwear protecting against chemicals

EN 133 Respiratory protective devices

Definitions and abbreviations

PC-TWA: Permissible Concentration-Time Weighted Average PC-STEL: Permissible Concentration-Short Term Exposure Limit

STEL: Short Term Exposure Limit

TEEL: Temporary Emergency Exposure Limit

IDLH: Immediately Dangerous to Life or Health Concentrations

The information provided in this Safety Data Sheet has been compiled by Dechra Ltd using a number of different sources, and is correct to the best of its knowledge, information and belief as at the date of its publication. However, Dechra Ltd makes no warranties, express or implied, in relation to the information set out in this Safety Data Sheet, including, without limitation, as to its accuracy or completeness.

The information provided is not a quality specification, and is prepared by way of guidance as to the safe handling, use, processing, storage, transportation, disposal and release of the relevant products referred to. The user is responsible for determining whether or not the product is fit for any particular purpose and/or suitable for the user's proposed method of use and application.

Copyright, 2017, Dechra Ltd. All rights reserved.

Copying and/or downloading of this information for the purpose of properly utilizing Dechra Ltd products is permitted provided that: (1) the information is copied in full with no changes unless prior written agreement is obtained from Dechra Ltd, and (2) neither the copy nor the original is resold or otherwise distributed for the purposes of making a profit thereon.